354 related articles for article (PubMed ID: 36481435)
1. Oligomeric α-synuclein and tau aggregates in NDEVs differentiate Parkinson's disease from atypical parkinsonisms.
Meloni M; Agliardi C; Guerini FR; Zanzottera M; Bolognesi E; Picciolini S; Marano M; Magliozzi A; Di Fonzo A; Arighi A; Fenoglio C; Franco G; Arienti F; Saibene FL; Navarro J; Clerici M
Neurobiol Dis; 2023 Jan; 176():105947. PubMed ID: 36481435
[TBL] [Abstract][Full Text] [Related]
2. Oligomeric Alpha-Synuclein and STX-1A from Neural-Derived Extracellular Vesicles (NDEVs) as Possible Biomarkers of REM Sleep Behavior Disorder in Parkinson's Disease: A Preliminary Cohort Study.
Meloni M; Agliardi C; Guerini FR; Saibene FL; Milner AV; Zanzottera M; Bolognesi E; Puligheddu M; Figorilli M; Navarro J; Clerici M
Int J Mol Sci; 2023 May; 24(10):. PubMed ID: 37240185
[TBL] [Abstract][Full Text] [Related]
3. Phosphorylated α-synuclein and phosphorylated tau-protein in sural nerves may contribute to differentiate Parkinson's disease from multiple system atrophy and progressive supranuclear paralysis.
Rong Z; Shen F; Wang Y; Sun L; Wu J; Zhang H; Yuan Y; Jiang W; Li X; Ji P; Zhang K
Neurosci Lett; 2021 Jun; 756():135964. PubMed ID: 34022266
[TBL] [Abstract][Full Text] [Related]
4. A panel of nine cerebrospinal fluid biomarkers may identify patients with atypical parkinsonian syndromes.
Magdalinou NK; Paterson RW; Schott JM; Fox NC; Mummery C; Blennow K; Bhatia K; Morris HR; Giunti P; Warner TT; de Silva R; Lees AJ; Zetterberg H
J Neurol Neurosurg Psychiatry; 2015 Nov; 86(11):1240-7. PubMed ID: 25589779
[TBL] [Abstract][Full Text] [Related]
5. Salivary alpha-synuclein in the diagnosis of Parkinson's disease and Progressive Supranuclear Palsy.
Vivacqua G; Suppa A; Mancinelli R; Belvisi D; Fabbrini A; Costanzo M; Formica A; Onori P; Fabbrini G; Berardelli A
Parkinsonism Relat Disord; 2019 Jun; 63():143-148. PubMed ID: 30796010
[TBL] [Abstract][Full Text] [Related]
6. α-Synuclein seed amplification assay as a diagnostic tool for parkinsonian disorders.
Fernandes Gomes B; Farris CM; Ma Y; Concha-Marambio L; Lebovitz R; Nellgård B; Dalla K; Constantinescu J; Constantinescu R; Gobom J; Andreasson U; Zetterberg H; Blennow K
Parkinsonism Relat Disord; 2023 Dec; 117():105807. PubMed ID: 37591709
[TBL] [Abstract][Full Text] [Related]
7. Discriminating among degenerative parkinsonisms using advanced (123)I-ioflupane SPECT analyses.
Badoud S; Van De Ville D; Nicastro N; Garibotto V; Burkhard PR; Haller S
Neuroimage Clin; 2016; 12():234-40. PubMed ID: 27489771
[TBL] [Abstract][Full Text] [Related]
8. Dopamine transporter SPECT imaging in Parkinson's disease and atypical Parkinsonism: a study of 137 patients.
Constantinides VC; Souvatzoglou M; Paraskevas GP; Chalioti M; Stefanis L; Kapaki E
Neurol Sci; 2023 May; 44(5):1613-1623. PubMed ID: 36658411
[TBL] [Abstract][Full Text] [Related]
9. Post mortem cerebrospinal fluid α-synuclein levels are raised in multiple system atrophy and distinguish this from the other α-synucleinopathies, Parkinson's disease and Dementia with Lewy bodies.
Foulds PG; Yokota O; Thurston A; Davidson Y; Ahmed Z; Holton J; Thompson JC; Akiyama H; Arai T; Hasegawa M; Gerhard A; Allsop D; Mann DM
Neurobiol Dis; 2012 Jan; 45(1):188-95. PubMed ID: 21856424
[TBL] [Abstract][Full Text] [Related]
10. CSF α-synuclein and UCH-L1 levels in Parkinson's disease and atypical parkinsonian disorders.
Mondello S; Constantinescu R; Zetterberg H; Andreasson U; Holmberg B; Jeromin A
Parkinsonism Relat Disord; 2014 Apr; 20(4):382-7. PubMed ID: 24507721
[TBL] [Abstract][Full Text] [Related]
11. The evolution of diagnosis from symptom onset to death in progressive supranuclear palsy (PSP) and corticobasal degeneration (CBD) compared to Parkinson's disease (PD).
Swallow DMA; Counsell CE
J Neurol; 2023 Jul; 270(7):3464-3474. PubMed ID: 36971841
[TBL] [Abstract][Full Text] [Related]
12. α-Synuclein in blood exosomes immunoprecipitated using neuronal and oligodendroglial markers distinguishes Parkinson's disease from multiple system atrophy.
Dutta S; Hornung S; Kruayatidee A; Maina KN; Del Rosario I; Paul KC; Wong DY; Duarte Folle A; Markovic D; Palma JA; Serrano GE; Adler CH; Perlman SL; Poon WW; Kang UJ; Alcalay RN; Sklerov M; Gylys KH; Kaufmann H; Fogel BL; Bronstein JM; Ritz B; Bitan G
Acta Neuropathol; 2021 Sep; 142(3):495-511. PubMed ID: 33991233
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of α-synuclein in CNS-originating extracellular vesicles for Parkinsonian disorders: A systematic review and meta-analysis.
Taha HB; Ati SS
CNS Neurosci Ther; 2023 Dec; 29(12):3741-3755. PubMed ID: 37416941
[TBL] [Abstract][Full Text] [Related]
14. Accuracy of a panel of 5 cerebrospinal fluid biomarkers in the differential diagnosis of patients with dementia and/or parkinsonian disorders.
Hall S; Öhrfelt A; Constantinescu R; Andreasson U; Surova Y; Bostrom F; Nilsson C; Håkan W; Decraemer H; Någga K; Minthon L; Londos E; Vanmechelen E; Holmberg B; Zetterberg H; Blennow K; Hansson O
Arch Neurol; 2012 Nov; 69(11):1445-52. PubMed ID: 22925882
[TBL] [Abstract][Full Text] [Related]
15. Analysis of biomarkers in speculative CNS-enriched extracellular vesicles for parkinsonian disorders: a comprehensive systematic review and diagnostic meta-analysis.
Taha HB; Bogoniewski A
J Neurol; 2024 Apr; 271(4):1680-1706. PubMed ID: 38103086
[TBL] [Abstract][Full Text] [Related]
16. CSF biomarkers β-amyloid, tau proteins and a-synuclein in the differential diagnosis of Parkinson-plus syndromes.
Constantinides VC; Paraskevas GP; Emmanouilidou E; Petropoulou O; Bougea A; Vekrellis K; Evdokimidis I; Stamboulis E; Kapaki E
J Neurol Sci; 2017 Nov; 382():91-95. PubMed ID: 29111028
[TBL] [Abstract][Full Text] [Related]
17. Efficient RT-QuIC seeding activity for α-synuclein in olfactory mucosa samples of patients with Parkinson's disease and multiple system atrophy.
De Luca CMG; Elia AE; Portaleone SM; Cazzaniga FA; Rossi M; Bistaffa E; De Cecco E; Narkiewicz J; Salzano G; Carletta O; Romito L; Devigili G; Soliveri P; Tiraboschi P; Legname G; Tagliavini F; Eleopra R; Giaccone G; Moda F
Transl Neurodegener; 2019; 8():24. PubMed ID: 31406572
[TBL] [Abstract][Full Text] [Related]
18. Alpha-Synuclein Protofibrils in Cerebrospinal Fluid: A Potential Biomarker for Parkinson's Disease.
von Euler Chelpin M; Söderberg L; Fälting J; Möller C; Giorgetti M; Constantinescu R; Blennow K; Zetterberg H; Höglund K
J Parkinsons Dis; 2020; 10(4):1429-1442. PubMed ID: 33016895
[TBL] [Abstract][Full Text] [Related]
19. Presence of Skin α-Synuclein Deposits Discriminates Parkinson's Disease from Progressive Supranuclear Palsy and Corticobasal Syndrome.
Giannoccaro MP; Avoni P; Rizzo G; Incensi A; Infante R; Donadio V; Liguori R
J Parkinsons Dis; 2022; 12(2):585-591. PubMed ID: 34864689
[TBL] [Abstract][Full Text] [Related]
20. Degeneration in different parkinsonian syndromes relates to astrocyte type and astrocyte protein expression.
Song YJ; Halliday GM; Holton JL; Lashley T; O'Sullivan SS; McCann H; Lees AJ; Ozawa T; Williams DR; Lockhart PJ; Revesz TR
J Neuropathol Exp Neurol; 2009 Oct; 68(10):1073-83. PubMed ID: 19918119
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
